Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,142 across all filing types
Latest filing 2011-09-20 M&A Activity
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is a communication letter from Johnson & Johnson regarding an organizational change related to the acquisition of Synthes. It references a Form S-4 registration statement and a proxy statement/prospectus that will be filed and sent to shareholders. The text includes disclaimers about forward-looking statements and directs readers to the SEC website for the actual filings. The document itself does not contain financial statements or detailed financial data but rather serves as an informational letter about the acquisition process and organizational changes. It also explicitly states that the proxy statement/prospectus will be sent to shareholders and that the registration statement and other documents are available on the SEC website. This indicates that the document is a communication related to merger activity but is not the merger filing itself (like a Form S-4 or DEFM14A). It is more of a communication or announcement related to the merger process. Given the content and context, the document fits best as a Transaction Announcement related to merger activity, but since it is not a formal merger filing, the closest specific category is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is over 10,000 characters, so it is not a brief announcement or a report publication announcement. Therefore, the classification is M&A Activity (TAR) with high confidence.
2011-09-20 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-15 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-15 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-15 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-15 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-15 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.